MX2017004558A - Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. - Google Patents
Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.Info
- Publication number
- MX2017004558A MX2017004558A MX2017004558A MX2017004558A MX2017004558A MX 2017004558 A MX2017004558 A MX 2017004558A MX 2017004558 A MX2017004558 A MX 2017004558A MX 2017004558 A MX2017004558 A MX 2017004558A MX 2017004558 A MX2017004558 A MX 2017004558A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- valproic acid
- prevention
- thrombus formation
- fibrin deposition
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 229960000604 valproic acid Drugs 0.000 title abstract 3
- 102000009123 Fibrin Human genes 0.000 title abstract 2
- 108010073385 Fibrin Proteins 0.000 title abstract 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title abstract 2
- 208000007536 Thrombosis Diseases 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 230000008021 deposition Effects 0.000 title abstract 2
- 229950003499 fibrin Drugs 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona ácido valproico o una sal farmacéuticamente aceptable del mismo, para utilizarse en el tratamiento o prevención de un trastorno patológico asociado con un exceso de deposición de fibrina y/o formación de trombos, en donde el tratamiento comprende tratar a un paciente con ácido valproico o una sal farmacéuticamente aceptable del mismo, de una manera específica, y formulaciones para usarse o diseñadas para usarse en tales tratamientos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417828.9A GB201417828D0 (en) | 2014-10-08 | 2014-10-08 | New methods and compositions |
| PCT/GB2015/052950 WO2016055797A2 (en) | 2014-10-08 | 2015-10-08 | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004558A true MX2017004558A (es) | 2017-12-14 |
Family
ID=51947070
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004558A MX2017004558A (es) | 2014-10-08 | 2015-10-08 | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. |
| MX2022007221A MX2022007221A (es) | 2014-10-08 | 2017-04-06 | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007221A MX2022007221A (es) | 2014-10-08 | 2017-04-06 | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10111845B2 (es) |
| EP (2) | EP3203997B1 (es) |
| JP (2) | JP6787901B2 (es) |
| KR (2) | KR20250005512A (es) |
| CN (3) | CN107205975A (es) |
| AU (1) | AU2015329795B2 (es) |
| BR (1) | BR112017007144A2 (es) |
| CA (2) | CA3234641A1 (es) |
| CL (1) | CL2017000866A1 (es) |
| DK (1) | DK3203997T3 (es) |
| ES (1) | ES2913225T3 (es) |
| GB (1) | GB201417828D0 (es) |
| HU (1) | HUE058316T2 (es) |
| IL (1) | IL251142B (es) |
| MX (2) | MX2017004558A (es) |
| MY (1) | MY192055A (es) |
| PL (1) | PL3203997T3 (es) |
| RU (1) | RU2732761C2 (es) |
| SG (1) | SG11201702058XA (es) |
| WO (1) | WO2016055797A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PT3105226T (pt) | 2014-02-13 | 2019-11-06 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| ME03654B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| PL3439649T3 (pl) * | 2016-04-08 | 2024-03-18 | Cereno Scientific Ab | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
| WO2017175010A1 (en) * | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| US20230069590A1 (en) * | 2020-01-16 | 2023-03-02 | The Regents Of The University Of Michigan | Concentrated sodium valproate for rapid delivery |
| CN111450072B (zh) * | 2020-05-07 | 2022-07-15 | 江苏艾立康医药科技有限公司 | 一种替格瑞洛控释片及其制备方法 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| ATE68346T1 (de) | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
| US6713086B2 (en) * | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| HK1042427A1 (zh) | 1999-09-30 | 2002-08-16 | Penwest Pharmaceuticals Co. | 用於高溶度药物的持续释放基质方法 |
| AT408718B (de) | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| US7090858B2 (en) | 2001-08-09 | 2006-08-15 | Swaminathan Jayaraman | Coated filter bag material for oral administration of medicament in liquid and methods of making same |
| CN1668312A (zh) * | 2002-05-13 | 2005-09-14 | 洛杉矶儿童医院 | 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| DE602004014723D1 (de) | 2004-04-30 | 2008-08-14 | Desitin Arzneimittel Gmbh | Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20050276848A1 (en) | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| EP1937236A2 (en) | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| PT1937650E (pt) | 2005-09-08 | 2011-09-21 | S Bio Pte Ltd | Compostos heterocíclicos |
| ES2317450T3 (es) | 2006-01-11 | 2009-04-16 | Teva Pharmaceutical Industries Ltd. | Formulacion de liberacion controlada de acido valproico y sus derivados. |
| US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| EP2004234A2 (en) | 2006-04-06 | 2008-12-24 | Novartis AG | Combination of organic compounds |
| MX370905B (es) | 2006-08-31 | 2020-01-09 | Adare Pharmaceuticals Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
| WO2008154402A2 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| CN101947209B (zh) | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| WO2012120262A1 (en) | 2011-03-09 | 2012-09-13 | Larsson Pia | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
| EP2755648B1 (en) | 2011-09-13 | 2017-03-08 | Pharmacyclics LLC | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| WO2017175010A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| PL3439649T3 (pl) | 2016-04-08 | 2024-03-18 | Cereno Scientific Ab | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
-
2014
- 2014-10-08 GB GBGB1417828.9A patent/GB201417828D0/en not_active Ceased
-
2015
- 2015-10-08 SG SG11201702058XA patent/SG11201702058XA/en unknown
- 2015-10-08 PL PL15790632T patent/PL3203997T3/pl unknown
- 2015-10-08 EP EP15790632.2A patent/EP3203997B1/en active Active
- 2015-10-08 CA CA3234641A patent/CA3234641A1/en active Pending
- 2015-10-08 CA CA2964041A patent/CA2964041C/en active Active
- 2015-10-08 IL IL251142A patent/IL251142B/en unknown
- 2015-10-08 AU AU2015329795A patent/AU2015329795B2/en active Active
- 2015-10-08 KR KR1020247041714A patent/KR20250005512A/ko active Pending
- 2015-10-08 CN CN201580055071.4A patent/CN107205975A/zh active Pending
- 2015-10-08 BR BR112017007144A patent/BR112017007144A2/pt not_active Application Discontinuation
- 2015-10-08 US US15/517,229 patent/US10111845B2/en active Active
- 2015-10-08 EP EP21216908.0A patent/EP4066825A1/en active Pending
- 2015-10-08 JP JP2017538468A patent/JP6787901B2/ja active Active
- 2015-10-08 RU RU2017114933A patent/RU2732761C2/ru active
- 2015-10-08 MY MYPI2017701203A patent/MY192055A/en unknown
- 2015-10-08 CN CN202211237344.5A patent/CN115721635A/zh active Pending
- 2015-10-08 DK DK15790632.2T patent/DK3203997T3/da active
- 2015-10-08 KR KR1020177011492A patent/KR20170063857A/ko not_active Ceased
- 2015-10-08 HU HUE15790632A patent/HUE058316T2/hu unknown
- 2015-10-08 WO PCT/GB2015/052950 patent/WO2016055797A2/en not_active Ceased
- 2015-10-08 ES ES15790632T patent/ES2913225T3/es active Active
- 2015-10-08 MX MX2017004558A patent/MX2017004558A/es unknown
- 2015-10-08 CN CN202211231367.5A patent/CN115581691A/zh active Pending
-
2017
- 2017-04-06 MX MX2022007221A patent/MX2022007221A/es unknown
- 2017-04-07 CL CL2017000866A patent/CL2017000866A1/es unknown
-
2018
- 2018-09-19 US US16/135,639 patent/US11400064B2/en active Active
-
2020
- 2020-10-29 JP JP2020181522A patent/JP7305605B2/ja active Active
-
2022
- 2022-08-01 US US17/816,486 patent/US12245999B2/en active Active
-
2025
- 2025-03-10 US US19/075,243 patent/US20250241880A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004558A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| PH12017500493A1 (en) | Combination therapy | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| MX2017002948A (es) | Métodos de tratamiento para la sarcoidosis pulmonar. | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| EA201691335A1 (ru) | Гексагидрофуропирролы в качестве ингибиторов pde1 | |
| WO2015142865A3 (en) | Metakaryocidal treatments | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| PL3689341T3 (pl) | Gabapentyna okulistyczna do leczenia deepitelializacji rogówki | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| IL258316A (en) | A combination of trazodone and gabapentin for the treatment of pain | |
| MX2019006143A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| CL2018002930A1 (es) | (+)-azasetron para uso en el tratamiento de desórdenes de oído. | |
| CL2015001705A1 (es) | Uso de pidotimod para tratar la psoriasis | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |